Gary Giampetruzzi: Is Small Pharma Next for DOJ Enforcement?
In a commentary on FCPA Blog, Gary Giampetruzzi, global vice-chair of the Investigations and White Collar Defense and Life Sciences Departments and a partner in the Litigation Department of Paul Hastings in New York, says the Department of Justice may be turning its attention away from big pharmaceutical corporations in favor of investigating Anti-Kickback and FCPA allegations against smaller pharma firms.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every case digest, six days a week.
$750/year